ENVB Stock Falls in After-Hours Trading Due to Increased Q4 Losses Despite Advancements in Psychiatry Drug Research

Written by Emily J. Thompson, Senior Investment Analyst

Source: stocktwits

Updated: 4 days ago

0mins

ENVB+8.38%

PSIL+6.02%

Should l Buy ENVB?

Source: stocktwits

Company Progress: The company is completing pre-clinical studies for its lead candidate EB-003, which aims to treat mental health conditions, and is preparing to submit an application to the FDA for human trials.
Financial Performance: Enveric Biosciences reported a net loss of $4 million for Q4 2025, an increase from the $3.2 billion loss reported in the same quarter of 2024.
Market Reaction: Following the financial report, shares of Enveric Biosciences fell by 4%, reflecting ongoing bearish sentiment in the market, with the stock losing nearly 90% of its value over the past year.
Future Plans: The company is optimistic about the potential of EB-003, which engages both 5-HT2A and 5-HT1B receptors, to significantly impact the treatment of chronic depression and related disorders.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ENVB?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ENVB

About ENVB

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Enveric Biosciences Reports Q4 2025 Financial Results

2 days agoseekingalpha

Financial Overview: Enveric Biosciences reported a GAAP EPS of -$6.12 for Q4 2025, indicating significant challenges in profitability that could undermine investor confidence.
Cash Position: As of December 31, 2025, the company had $4.7 million in cash on hand, suggesting that its liquidity may be insufficient to support future operations and R&D activities under the current financial circumstances.
Funding Situation: Throughout 2025, the company raised gross proceeds of $12.2 million through various offerings, which, while alleviating short-term cash pressures, remains inadequate to cover ongoing losses.
Market Reaction: Following Gilgamesh's withdrawal of its patent petition, Enveric's stock saw a rise; however, the announcement of a $1.5 million registered direct offering and warrant placement led to a decline in share price, reflecting market concerns about the company's long-term prospects.

Enveric Biosciences Advances EB-003 Clinical Research

4 days agostocktwits

Clinical Research Progress: Enveric Biosciences is completing pre-clinical studies for its lead candidate EB-003 and plans to submit an application to the FDA to initiate human trials, aiming to deliver fast-acting, durable antidepressant and anxiolytic effects to address urgent mental health needs.
Poor Financial Performance: The company reported a net loss of $4 million for Q4 2025, an increase from the $3.2 million loss in the same quarter of 2024, reflecting pressure on its R&D and operations that may impact future funding capabilities.
Negative Market Reaction: Following the earnings report, ENVB shares fell 4% in after-hours trading, indicating investor concerns over the company's financial health, with the stock losing nearly 90% of its value over the past 12 months, suggesting a lack of market confidence.
Future Plans: The company aims to submit a streamlined IND application in 2026 to initiate the first-in-human Phase 1 clinical trial for EB-003, with CEO Joseph Tucker expressing optimism about the drug's dual mechanism of action potentially making a significant impact on mental health diseases, which have seen little innovation for decades.